Hepatocellular carcinoma cell proliferation pathway (HCC proliferation pathway)

The hepatocellular carcinoma (HCC) cell proliferation pathway is a complex network of intracellular signaling cascades that drive the uncontrolled growth and survival of liver cancer cells [KEGG: hsa05225]. It is not a single molecular target but a collection of pathways, including the Raf/MEK/ERK (MAPK) and PI3K/Akt/mTOR cascades, which are frequently activated by upstream receptor tyrosine kinases such as VEGFR and FGFR [PubMed: 30103530]. These pathways integrate signals from the tumor microenvironment to promote cell cycle progression and evade apoptosis, often exacerbated by mutations in genes like CTNNB1 (beta-catenin) or TP53 [NIH/NCI]. Therapeutic management of advanced HCC primarily utilizes multi-kinase inhibitors like sorafenib and lenvatinib, which target multiple components of these signaling networks to inhibit both tumor cell proliferation and angiogenesis [StatPearls: Hepatocellular Carcinoma]. Because this target encompasses a broad array of proteins rather than a single receptor or enzyme, it represents a systemic biological process that is central to oncogenesis but requires multi-targeted or combination therapies for effective inhibition.

Other names

HCC signaling networkHepatoma cell growth pathwayLiver cancer proliferation signaling

Inhibition of multiple signaling nodes, primarily through multi-kinase inhibitors that block VEGFR, PDGFR, and the Raf/MEK/ERK cascade, leading to reduced tumor cell growth and vascularization.